In addition, the enzastaurin-pemetrexed combination significantly reduced Akt phosphorylation, which may explain the increased apoptosis found in the pemetrexed-erlotinib combination in the studied NSCLC cell lines. Here, AKT1 is linked to non-small cell lung carcinoma.